Protocol Ledger

NCT06549465 · Phase II · RECRUITING

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

Interventional Phase II clinical trial protocol NCT06549465 sponsored by Convergent Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-08-06 Enrollment: 93 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06549465
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)93 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06549465
Protocol FieldVerified Registry Value
NCT IdentifierNCT06549465
Consolidated Lead SponsorConvergent Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment93 participants (ESTIMATED)
Registered Start Date2024-08-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI